ITGAV and urinary bladder carcinoma: In this study, the role of ITGAV, which are highly expressed in bladder carcinomas, and its potential as a drug target in bladder cancer were investigated both by treatment with the ITGAV integrin-inhibitor GLPG0187 and knockdown of ITGAV.